Article Details

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its ... - PR Newswire UK

Retrieved on: 2023-01-04 00:05:07

Tags for this article:

Click the tags to see associated articles and topics

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its ... - PR Newswire UK. View article details on hiswai:

Excerpt

"The ability to leverage synthetic biology to engineer cell therapies will help drive innovative solutions for solid tumor cancer treatment.

Article found on: www.prnewswire.co.uk

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up